drugset / Trial / NCT04938232
Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL
Phase 2
Active not recruiting
13 enrolled
Dana-Farber Cancer Institute
Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is looking at the effects of Ipilimumab when it is given alone or in combination with Nivolumab to patients with relapsed or refractory classic Hodgkin's lymphoma (cHL). The names of the study drugs involved in this study are: * Ipilimumab * Nivolumab
Timeline
- Start
- 2021-06-04
- Primary completion
- 2024-04-01
- Completion
- 2026-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | — | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |